Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Intrarosa (Prasterone) for Postmenopausal Vulvovaginal Atrophy
NCT04982692Phase 3Completed
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Sep 2021
- Primary completion
- Jan 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal vulvovaginal atrophy (VVA) comparing Intravaginal prasterone with Placebo ovules (2 arms). Primary endpoints: Change in the dyspareunia severity score at 12 weeks, Change in the vaginal pH at 12 weeks and 2 more. Started Sep 2021; status: completed.
02
Drugs
dehydroepiandrosterone
03
Conditions
postmenopausal vulvovaginal atrophy (VVA)
Beyond the preview
Go deeper on NCT04982692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982692.